Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20262879 | 0.98 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1TSHRRECQLL3MBTL3 | |
| SCHEMBL427383 | 0.82 | SIGMAR1 (0.47) | ALDH1A1TSHRKDM4E | |
| SCHEMBL2203366 | 0.81 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1TSHRRECQLL3MBTL3 | |
| SCHEMBL25413163 | 0.79 | SIGMAR1 (0.41) | ALDH1A1TSHRKDM4E | |
| SCHEMBL1775624 | 0.79 | SIGMAR1 (0.44) | ALDH1A1TSHRKDM4E | |
| SCHEMBL1406665 | 0.78 | KDM1A (0.36) | ALDH1A1KDM4EKDM1A | |
| SCHEMBL1161434 | 0.77 | KMT2A (0.49) | L3MBTL1ALDH1A1TSHRRECQLL3MBTL3 | |
| SCHEMBL13804467 | 0.77 | KMT2A (0.49) | L3MBTL1ALDH1A1TSHRRECQLL3MBTL3 | |
| SCHEMBL12464314 | 0.77 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1TSHRRECQLL3MBTL3 | |
| SCHEMBL21949873 | 0.74 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1TSHRRECQLL3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1802612-A1 | NOVEL B1 BRADYKININ RECEPTOR ANTAGONISTS | Amgen, Inc (US) | 2007-07-04 | — | — | EP | disclosed |
| EP-1688420-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006044412-A1 | NOVEL B1 BRADYKININ RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | GTF3C5, ZC3HAV1, POLI | L3MBTL1 4165/4885ALDH1A1 596/4885TSHR 4648/4885 |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | GTF3C5, ZC3HAV1, POLI | L3MBTL1 4165/4885ALDH1A1 596/4885TSHR 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.